Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Atherothrombosis J Am Coll Cardiol. 2012;60(10): doi: /j.jacc Relation Between Components of Ideal Cardiovascular Health and Outcome Incident cardiovascular disease (CVD) adjusted for age, race, and sex in the ARIC (Atherosclerosis Risk in Communities) study. Figure Legend:

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Atherothrombosis J Am Coll Cardiol. 2012;60(10): doi: /j.jacc Projected Increases in CVD Prevalence and Related Costs in the United States (A) Crude prevalence and (B) costs related to cardiovascular disease (CVD) are expected to increase markedly during the next 2 decades. Figure Legend:

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Atherothrombosis J Am Coll Cardiol. 2012;60(10): doi: /j.jacc Event Rates in the PROSPECT Study According to IVUS-Based Plaque Features Graphs compare event rates in the PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) study of thin-cap fibroatheromas (TCFA [example shown in box]) (red bars), n = 595, versus non-TCFA lesions (blue bars), n = 2,114, and also according to minimal luminal area (MLA) and plaque burden (PB). CI = confidence interval; IVUS = intravascular ultrasonography. Figure Legend:

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Atherothrombosis J Am Coll Cardiol. 2012;60(10): doi: /j.jacc Depiction of Intraplaque Hemorrhage by MRI Examples of magnetic resonance imaging (MRI) in 2 patients with carotid intraplaque bleeding (upper row) and without carotid intraplaque bleeding (bottom row). Direct thrombus imaging demonstrates high signal in a large right common carotid artery plaque in the first patient (A, arrowheads), which is absent in a similarly large plaque in the left common carotid artery in the second patient (D, arrowheads). Noncontrast angiograms (B and E, arrows) and contrast-enhanced angiograms (C and F) demonstrate no significant stenosis in either patient. Figure Legend:

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Atherothrombosis J Am Coll Cardiol. 2012;60(10): doi: /j.jacc Main Results of the AIM-HIGH Trial In the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides) trial, addition of niacin to statin therapy (red line) when compared to placebo (black line) did not result in a reduction of the primary outcome (coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, hospitalization for an acute coronary syndrome, or symptom-driven coronary or cerebral revascularization). No. = number. Figure Legend:

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Atherothrombosis J Am Coll Cardiol. 2012;60(10): doi: /j.jacc Odds of CHD According to HDL Cholesterol Efflux Capacity and Standard Risk Factors Odds ratios are adjusted by age and sex, and for continuous variables indicate odds per 1 SD increase. High-density lipoprotein (HDL) cholesterol efflux capacity is significantly protective of coronary heart disease (CHD). CI = confidence interval; LDL = low- density lipoprotein. Figure Legend:

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Atherothrombosis J Am Coll Cardiol. 2012;60(10): doi: /j.jacc Cumulative Incidence of Events by Rivaroxaban Dose in the ATLAS ACS 2–TIMI 51 Trial In the ATLAS ACS 2–TIMI 51 trial, (A, B) the primary efficacy endpoint (cardiovascular death, myocardial infarction, or stroke) is reduced by both rivaroxaban doses, but (C, D) only the smaller dose is associated with survival benefit. CI = confidence interval. Figure Legend:

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Atherothrombosis J Am Coll Cardiol. 2012;60(10): doi: /j.jacc Number of Preventive Drugs According to Regional Socioeconomic Status Medications taken for secondary prevention per person in the PURE (Prospective Urban Rural Epidemiological) study: no drug (dark gray bars), 1 drug (blue bars), 2 drugs (orange bars), or ≥3 drugs (light gray bars). Figure Legend: